INDV vs SUPN
INDV: A pharmaceutical company specialized in innovative treatments for substance use and mental health disorders. SUPN: A neuroscience-focused biopharmaceutical company dedicated to developing and commercializing innovative therapies for complex central nervous system disorders.
Side-by-side fundamentals
| Metric | INDV | SUPN | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $40.03 | $46.98 | |
| Market cap as of 2026-08-03 | $4.9B | $2.7B | |
| P/E as of 2026-08-03 | 19.43 | n/a | |
| PEG as of 2026-08-03 | 0.84 | n/a | |
| Net margin as of 2026-08-03 | +19.4% | -3.7% | INDV higher |
| Gross margin as of 2026-08-03 | +81.3% | +89.7% | SUPN higher |
| Operating margin as of 2026-08-03 | +24.4% | -7.8% | INDV higher |
| ROE as of 2026-08-03 | +159.1% | -2.7% | INDV higher |
| ROA as of 2026-08-03 | +19.1% | -2.0% | INDV higher |
| Debt / equity as of 2026-08-03 | 27.90 | 0.00 | SUPN lower |
| Revenue growth (YoY) as of 2026-08-03 | +10.3% | +16.3% | SUPN higher |
| Revenue CAGR (3y) SEC XBRL | +11.2% | +2.5% | INDV higher |
| Beta as of 2026-08-03 | 0.53 | 0.57 | |
| 1-year return as of 2026-07-27 close | +133.5% | +39.9% | INDV higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.